Cell Genesys’ GVAX (correction)
Executive Summary
Cell Genesys estimates the timing of the pre-planned interim analysis from VITAL-1, the first of two ongoing Phase III trials of GVAX immunotherapy for prostate cancer, to be in the first half of 2008. A recent article misstates that the interim analysis of two Phase III trials are scheduled for the second half of 2008 (1"The Pink Sheet" Oct. 29, 2007, p. 30)...
You may also be interested in...
Survival Endpoints, Rigorous Phase IIs May Boost Cancer Vaccines’ Success
SAN FRANCISCO - Stronger endpoints for survival and more rigorously designed Phase II trials are what will push the development of therapeutic cancer vaccines closer to the finish line, an industry panel said at a recent meeting at the Biotechnology Industry Organization Investor Forum
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.